Patient involvement in clinical trial design can facilitate the recruitment and retention of
participants as well as potentially increase the uptake of the tested intervention and the …

Significant progress has been made in understanding the genetic basis of autosomal
dominant polycystic kidney disease (ADPKD), quantifying disease manifestations in …

Novel treatment strategies for cardiac tissue regeneration are heading for the use of
engineered cardiac tissue made from induced pluripotent stem cell-derived cardiomyocytes …

Background: Intracranial aneurysms (IAs) result from abnormal enlargement of the arterial
lumen. IAs are mostly quiescent and asymptomatic, but their rupture leads to severe brain …

Background Pain has been identified as a core outcome for individuals with autosomal
dominant polycystic kidney disease (ADPKD), but no disease-specific pain assessment has …

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide.
Randomized controlled trials (RCTs) are the cornerstone to evaluate the efficacy of an …

Introduction In 1-and 3-year randomized trials, tolvaptan slowed kidney function decline in
subjects with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid …

Introduction Valid prediction models or predictors of disease progression in children and
young patients with autosomal dominant polycystic kidney disease (ADPKD) are lacking …

Introduction Pain is a critically important outcome in autosomal dominant polycystic kidney
disease (ADPKD); however, it is infrequently and inconsistently reported in clinical trials …

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder marked by the
development of cysts in the kidneys and other organs, leading to diverse clinical …